| Clinical Publications |
Scientific Publications |
| August 2025 |
Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment-free remission in chronic myeloid leukemia
Ravipati S et al. Leuk Res, August 2025
(epub ahead of print) |
The role of METTL14 in the progression of chronic myeloid leukemia
Zhang J et al. Hematology, August 2025
– open access publication |
Clinical features and t-cell repertoire of chronic myeloid leukemia patients who attempt discontinuation of tyrosine kinase inhibitors: The ISAC-TFR Study
Ureshino H et al. Cancer Med, August 2025 – open access publication |
Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review
Lahmouad M et al. Leuk Res Rep, August 2025 – open access publication |
| |
Beta-Catenin interacts with canonical RBPs including MSI2 to associate with a Wnt signalling mRNA network in myeloid leukemia cells
Wagstaff M et al. Oncogene, August 2025
– open access publication
|
| |
Hesperetin increases membrane progesterone receptor expression in human myeloid leukemia cells and reduces ROS
Hosseini SS et al. Med Oncol, August 2025 |
| |
Expression profiles of miR-411 and SPRY4 as indicator of disease progression and treatment in chronic myelogenous leukemia
Shabannezhad A et al. Sci Rep, August 2025 – open access publication |
| |
The roles of non-coding RNAs (ncRNAs) in the function of leukemia stem cells (LSCs): A comprehensive Review
Sharifi M et al. Discov Oncol, August 2025
– open access publication
|
| July 2025 |
|
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Apperley JF et al. Leukemia, July 2025
(epub ahead of publication)
– open access publication
|
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
Shi Y et al. Blood, July 2025
(epub ahead of print) |
Improving chronic myeloid leukemia management and quality of life:
Patient and physician survey of unmet needs from the CML SUN Study
Lang F et al. Haematologica, July 2025
(epub ahead of publication)
– open access publication |
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to allosteric ABL inhibitor asciminib
Muratcioglu S et al. Sci Signal, July 2025
(epub ahead of print)
– open access publication |
Management of chronic myeloid leukemia in 2025 - Review
Kantarjian H et al. Cancer, July 2025
- open access publication |
Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Yang H et al. Clin Epigenetics, July 2025
– open access publication |
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus
Giai V et al. Cancer, July 2025
– open access publication |
K562 chronic myeloid leukemia cells as a dual beta3-expressing functional cell line model to investigate the effect of combined alphaIbbeta3 and alphavbeta3 antagonism
Elsharif AA et al. Methods Protoc, July 2025
– open access publication |
Advancing quality of life in chronic myeloid leukemia: Where do we stand?
Lipton JH. Haematologica, July 2025
(epub ahead of print) |
CHK1-S, a splicing variant of CHK1, suppresses chronic myeloid leukemia
Lei H et al. Leuk Res, July 2025
(epub ahead of print) |
Potential therapeutic targets in chronic myeloid leukemia - Review
Bansal M and Varma M. Med Oncol, July 2025 |
Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells
Okabe S et al. Discov Oncol, July 2025
– open access publication |
How will genomic testing impact a clinician’s choice for managing chronic myeloid leukemia?
Sia J and Shanmunagathan N. Expert Rev Hematol, July 2025 (epub ahead of print) |
ZFAS1/STAT3 axis modulates imatinib resistance in chronic myeloid leukemia cells through glucose metabolism reprogramming
Yang L and Han Y. Front Oncol, July 2025
– open access publication |
Secondary malignancies after chronic myeloid leukemia upon TKI treatment: Population trends and outcomes
Zu Y et al. Br J Haematol, July 2025 (epub ahead of print) – open access publication |
Identification of a PAK6-mediated MDM2/p21 axis that modulated survival and cell cycle control of drug-resistant stem/progenitor cells in chronic myeloid leukemia
Wu A et al. Int J Mol Sci, July 2025
– open access publication |
Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitors
Park H et al. Ann Hematol, July 2025
(epub ahead of print)
– open access publication |
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
Ensafi Talemi F and Ghafouri-Fard S. Leuk Res Rep,
July 2025 – open access publication |
The incidence of vascular adverse events and usefulness of novel risk assessment tool of Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Watanabe et al. Cardiooncology, July 2025 – open access publication |
|
Reconstructing CML guidelines for first line treatment from two different points of view
Gambacorti-Passerini C et al. Blood Cancer J, July 2025
– open access publication |
|
A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: A narrative review
Ghasoub R et al. Front Oncol, July 2025
– open access publication
|
|
Using early biomarker change and treatment adherence to predict risk of relapse among patients with chronic myeloid leukemia who are in remission
Montano-Campos JF et al. JCO Clin Cancer Inform, July 2025
|
|
Comparing therapeutic effects across tyrosine kinase inhibitors: Chronic myeloid leukemia outcomes and analysis of influencing factors
Zhang Z et al. Medicine(Baltimore), July 2025
|
|
Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy
Hayashino K et al. Int J Hematol, July 2025 (epub ahead of print) |
|
Measurable residual disease in hematologic malignancies: A biomarker in search of a standard
Shandhok NS and Sekeres MA. EClinicalMedicine, July 2025
(epub ahead of print) |
|
Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia
Lopez-Fernández E et al. Ann Hematol, July 2025 (epub ahead of print)
|
|
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors – Review
Gullaksen SE et al. Leuk Lymphoma, July 2025 – open access publication
|
|
|
Associations between waist circumference, body mass index, HDL cholesterol level, and risk of chronic myeloid leukemia
Kim KY et al. Cancer Epidemiol Biomarkers Prev, July 2025
|
|
| June 2025 |
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter? - Review
Dalgetty M and Cortes J. Blood, June 2025
|
miRNA expression based modulation: A new paradigm for the treatment of chronic myeloid leukemia - Review
Ansari S and Varma M. Biochim Biophy Acta Rev Cancer, June 2025
(epub ahead of print) |
Concomitant T315I and E459K mutations in chronic myeloid leukemia:
A case report
Zhou X et al. Oncol Lett, June 2025
– open access publication
|
Metamizole limits proliferation in chronic myeloid leukemia cells and triggers apoptosis via the bax/bal-2/caspase-3 cascade
Maytalman E et al. Med Oncol, June 2025 – open access publication |
Clinical features and treatment response to tyrosine kinase inhibitors in chronic myeloid leukemia patients with atypical BCR::ABL1 transcript
Wang H et al Leuk Res, June 2025
(epub ahead of print)
|
Overexpression of miR-29a and miR-29b is involved in imatinib resistance via abrogated NF1 expression and increased ERK1/2 activation in chronic myeloid leukemia cells
Tsubaki M et al. Med Oncol, June 2025 |
Risk factors, behavior, and adverse health outcomes of financial toxicity in adult chronic myeloid leukemia survivors: A theory-based structural equation model
Jin R et al. Support Care Cancer, June 2025
|
The telomere length signature in leukemias – from molecular mechanisms underlying telomere shortening to immunotherapeutic options against telomerase
Baliou S et al. Cancers(Basel), June 2025 – open access publication |
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic-phase: A prospective, observational study – SIMPLICITY
Mauro MJ et al. Leuk Lymphoma, June 2025
(epub ahead of print)
– open access publication |
Machine learning driven dashboard for chronic myeloid leukemia prediction using protein sequences
Ahmed W et al. PLoS One, June 2025
– open access publication
|
Which is the best tyrosine kinase inhibitor for newly diagnosed chronic myelogenous leukemia? - Review
Shanmunagathan N et al. Am Soc Clin Oncol Educ Book, June 2025
– open access publication |
Uncovering putative causal non-coding RNAs in acute and chronic myeloid leukemia: A genome-wide Mendelian Randomisation Study
Jung S et al. Cancer Res Treat, June 2025
(epub ahead of print)
– open access publication
|
Asciminib for Philadelphia chromosome-positive leukemias
Hughes TP et al. Haematologica, June 2025 (epub ahead of print)
– open access publication |
BCR-ABL: The mastermind behind chronic myeloid leukemia – Review
Shammas T et al. Cytokine Growth Factor Rev, June 2025
– open access publication |
Treatment-free remission in chronic myeloid leukemia: Revisiting the “W” questions
Bruzzese A et al. Eur J Haematol, June 2025
(epub ahead of print)
– open access publication |
SUMOylation facilitates the stability of BCR-ABL to promote chronic myeloid leukemia progression
Zhang L et al. Oncogene, June 2025 |
SOHO state of the art updates and next questions: Combination therapy in chronic myeloid leukemia chronic-phase – Review
Costa A and Breccia M. Clin Lymphoma Myeloma Leuk, June 2025 |
Metabolomic profiling and bioanalysis of chronic myeloid leukemia: Identifiying biomarker for treatment response and disease monitoring
Sayin S et al. Metabolite, June 2025
– open access publication |
Impact of tyrosine kinase inhibitors on thyroid function in chronic myeloid leukemia: A systematic review
Sardarova N et al. Cureus, June 2025
– open access publication |
SMYD3 activates fatty acid beta-oxidation to promote self-renewal of leukemia stem cells
Zhou M et al. Cancer Res, June 2025 |
Olverembatinib in chronic myeloid leukemia: Is less actually better?
Perusini MA and Kim DDH. Haematologica, June 2025 (epub ahead of print)
– open access publication |
Genetic variants in oxidative stress-related genes and their impact on prognosis and treatment response in chronic myeloid leukemia patients
Alves R et al. Int J Mol, June 2025
– open access publication |
Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia
Bourne G et al. Cancers(Basel), June 2025
– open access publication |
|
Innovative rapid screening for complex BCR-ABL kinase domain mutations in TKI-treated leukemia patients
Lan Y et al. Br J Cancer, June 2025 (epub ahead of print) |
|
Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under conditions, such as the de novo cases:
A case series of the novo CML-BC treated with ponatonib and no transplantation
Koyabu S et al. Leuk Lymphoma, June 2025 |
|
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: A systematic review and meta analysis
Fan Z et al. Ther Adv Hematol, June 2025
– open access publication |
|
|
Treatment-free remission (TFR) in chronic-phase chronic myeloid leukemia
(CP-CML): Analysis of predictive factors and novel baseline scoring system to predict molecular relapse
Laganà A et al Eur J Haematol, June 2025 (epub ahead of print)
|
|
| May 2025 |
Chronic myeloid leukemia: A review
Jabbour E and Kantarjian H. JAMA, May 2025
|
Research of the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia
Feng X et al. Discov Oncol, May 2025 – open access publication |
Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis - Review
Smit Y et al. Support Care Cancer, May 2025
– open access publication
|
BCR-ABL: The molecular mastermind behind chronic myeloid leukemia – Review
Shammas T et al. Cytokine Growth Factor Rev, May 2025
(epub ahead of print)
– open access publication |
Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in CML: Insights from a multicenter retrospective study in real-world practice
Hibino Y et al. Leuk Res, May 2025
|
Structure and dynamics of the ABL1 tyrosine kinase and its important role in chronic myeloid leukemia - Review
Irgit A et al. Arch Pharm (Weinheim),
May 2025 – open access publication |
Management of chronic-phase chronic myeloid leukemia in later lines:
A Hong Kong consensus recommendation
Cheung CYM et al. Ann Hematol, May 2025 (epub ahead of print)
|
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers - Review
Sicuranza A et al. Front Oncol, May 2025
– open access publication |
Real world evidence from 2 decades of first-line TKI therapy in chronic myeloid leukemia (CML): Insights from ACHO’s RENEHOC Registry
Abello Polo V et al. Clin Lymphoma Myeloma Leuk, May 2025
– open access publication |
BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake
Mancini C et al. Cancer Cell Int, May 2025
– open access publication |
Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617F mutation by combination therapy with asciminib and ropeginterferon alpha-2b in an elderly patient
Oka S et al. Int J Hematol, May 2025 (epub ahead of print)
|
GPX1 confers resistance to metabolic stress in BRC/ABL-T315I mutant chronic myeloid leukemia cells
Wang JD et al. Cell Death Disc, May 2025 – open access publication |
Asciminib remained superior versus bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Mauro MJ et al. Blood Adv, May 2025
(epub ahead of print) |
|
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patient failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trials
le Coutre P et al. Acta Haematol, May 2025
(epub ahead of print) |
|
Pharmacokinetic profile of novel reduced-dose Danziten TM (Nilotinib tablets) versus Tasigna TM (Nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis
Mauro MJ et al. Cancer Chemother Pharmacol, May 2025 – open access publication |
|
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC
Johnson-Ansah H et al. Leuk Res, May 2025
(epub ahead of print) |
|
Real-world efficacy profile of compassionate use of asciminib in an Italian, multi-resistant chronic-phase chronic myeloid leukemia (CP-CML) patient population
Breccia M et al. Hematol Oncol, May 2025
– open access publication |
|
Bosutinib for successful treatment-free remission in chronic myeloid leukemia
Fujioka Y et al. Cancer Med, May 2025
– open access publication |
|
Optimal depth of the treatment response before allogeneic hematopoietic transplantation for chronic myeloid leukemia in chronic phase
Okada Y et al. Am J Hematol, May 2025 (epub ahead of print)
– open access publication |
|
|
Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia: A review
Jajosky AN and Lichtman MA. Haematologica, May 2025 (epub ahead of print) – open access publication
|
|
| April 2025 |
Chronic myeloid leukemia Treatment (PDQ): Patient Version
PDQ Adult Treatment Editorial Board, April 2025 – open access publication
|
KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT(+) blast phase chronic myeloid leukemia
Kwon HJ et al. Mol Cancer, April 2025 – open access publication
|
Molecular response with Ascminib 20 mg QD in a patient intolerant to multiple TKIs
Stuckey R et al. Ann Hematol, April 2025
(epub ahead of print)
– open access publication
|
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia
Nygrén P et al. Blood, April 2025
– open access publication
|
Asciminib monotherapy in patients with chronic myeloid leukemia chronic-phase without BCR::ABL1 T315I treated with at least 2 prior tyrosine kinase inhibitors: Phase 1 final results
Hochhaus A et al. Leukemia, April 2025
(epub ahead of print)
– open access publication |
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
Bica V et al. Cell Commun Signal, April 2025 – open access publication |
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: Phase 1 study final results
Cortes JE et al. Leukemia, April 2025
(epub ahead of print)
– open access publication |
The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis
Thuy VT et al. Leuk Res, April 2025 |
Olverembatinib in chronic myeloid leukemia – Review of historical development, current status, and future research
Kantarjian H et al. Cancer, April 2025 |
Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia
Xie Y et al. Cell Death Dis, April 2025
– open access publication
|
Successful treatment-free remission after ponatinib discontinuation in pretreated patients with chronic myeloid leukemia in chronic-phase
Haddad FG et al. Clin Lymphoma Myeloma Leuk,
April 2025 |
SMAC mimetics in action in chronic myeloid leukemia
Turhan AG. Blood, April 20 |
CAR-T cell therapy in chronic myeloid leukemia patients with lymphoid blast crisis: A multicenter clinical analysis
Liu Y et al. Cancer Lett, April 2025 (epub ahead of print) |
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability
Mancini M et al. Clin Transl Med, April 2025
– open access publication |
Prognostic scoring system in chronic myeloid leukemia – Review
Lauseker M et al. Leukemia, April 2025
(epub ahead of print)
– open access publication |
Timing and trajectory of BCR::ABL1-driven chronic myeloid leukemia
Kamizela AE et al. Nature, April 2025
– open access publication |
How I individualize treatment for chronic-phase CML
Leyte-Vidal AM and Shah NP. Blood, April 2025 (epub ahead of print) |
|
Synergistic effect of asciminib with reduced doses of ponatinib in human Ph+ myeloid leukemia with the T315M mutation
Nguyen T et al. Int J Hematol, April 2025
(epub ahead of print)
– open access publication |
|
Tyrosine kinase inhibitor treatment patterns in patients with chronic-phase chronic myeloid leukemia:
A single centre data from China
Yuan MY et al. Clin Lymphoma Myeloma Leuk, April 2025 |
|
Incidence of cardiovascular events and carotid artery USG abnormalities in chronic myeloid leukemia patients on nilotinib therapy: A 20-year single center study
Jang Y et al. Clin Lymphoma Myeloma Leuk, April 2025 (epub ahead of print) |
|
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
Zhang X et al. Haematologica, April 2025
(epub ahead of print) – open access publication |
|
| March 2025 |
Twin pregnancy during treatment with asciminib for chronic myeloid leukemia – a care report
Gutierrez de Moraes Pereira GBBM. Ann Hematol, March 2025
(epub ahead of print)
– open access publication
|
PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3
Barik B et al. Cell Death Dis, March 2025
– open access publication
|
Nilotinib induced diabetes in Japanese patients with chronic myeloid leukemia
Iwamoto Y et al. Intern Med, March 2025
– open access publication
|
Different in vitro models of chronic myeloid leukemia show different characteristics: Biological replicates are not biologically equivalent
Cavalleri A et al. Cell Biol Int, March 2025 (epub ahead of print)
– open access publication |
Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B photography
Beeler JS et al. Haematologica, March 2025 – open access publication
|
Comprehensive analysis of tyrosine kinase inhibitor domain mutations and imatinib resistance in chronic myeloid leukemia patients
Dhangar S et al. Leuk Res, March 2025 (epub ahead of print)
|
Alternative routes of drug administration: Exposure of imatinib using different formulations
Fiebrich-Westra HB et al. Cancer Chemother Pharmacol, March 2025
|
Selective translational control by PABPC1 phase separation regulates blast crisis and therapy resistance in chronic myeloid leukemia
Sun C et al. Nat Cell Biol, March 2025 (epub ahead of print) |
Evaluation of leukemic stem cell (CD26+) in chronic myeloid leukemia patients with different molecular response and in treatment-free remission
Camado MF et al. Clin Exp Med, March 2025
– open access publication |
Asciminib: The tyrosine kinase inhibitor with a unique mode of action - Review
Jain AG and Cortes JE. Expert Opin Pharmacother, March 2025 (epub ahead of print) |
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway
Wang J et al. Nat Cancer, March 2025
(epub ahead of print) |
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter?
Dalgetty M and Cortes JE. Blood, March 2025
(epub ahead of print) |
| |
Imatinib and the dawn of precision cancer medicine
Druker BJ. Nat Med, March 2025 |
| |
Living, not just surviving with CML – quality of life to the front of the line
Lipton JH and Rea D. Leukemia, March 2025
(epub ahead of print) |
| |
Chronic myeloid leukemia: A review
Jabbour E and Kantarjian H. JAMA, March 2025
(epub ahead of print) |
| |
Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors
Rodrigues Moreira P et al. J Oncol Pharm Pract,
March 2025 (epub ahead of print) |
| |
Do we need another TKI for chronic myeloid leukemia?
Hjorth-Hansen H. Lancet Haematol, March 2025 |
| |
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study
Busque L et al. Blood Cancer J, March 2025
– open access publication |
| February 2025 |
Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving Olverembatinib: Quality of life matters!
Eşkazan AE. Cancer, February 2025 |
Autophagy and Cancer: Insights into molecular mechanisms and therapeutic approaches for chronic myeloid leukemia – Review
Kausar MA et al. Biomolecules, February 2025 – open access publication
|
Novel treatment strategies for chronic myeloid leukemia – Review
Cruz-Rodriguez N and Deininger MW. Blood, February 2025
|
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
Guoyun J et al. Exp Hematol, February 2025 – open access publication
|
Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia – Review
Guilhot F and Hehlmann R. Blood, February 2025
|
MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Box, Puma and Noxa expression levels in imatinib-resistant chronic myeloid leukemia cells
Kimura A et al. Biomed Rep, February 2025 – open access publication
|
Unrelated bone marrow transplantation for CML after liver transplantation
Watanabe M et al. Intern Med, February 2025
(epub ahead of print)
– open access publication
|
MiR-142 deficit in T-cells during blast crisis promotes chronic myeloid leukemia immune escape
Chen F et al. Nat Commun, February 2025 – open access publication
|
Treatment-emergent resistance to asciminib in chronic myeloid leukemia patients due to myristoyl-binding pocket-mutant of BCR::ABL1/A337V can be effectively overcome with dasatinib treatment
Batar P et al. Curr Oncol, February 2025
– open access publication
|
Low-dose bee venom as a potential target against human chronic myeloid leukemia cells
Halici H et al. Protein J, February 2025
(epub ahead of print)
|
A CML patient carrying BCR::ABL1 splicing variant did not experience blast crisis for 15 years without responding to various TKIs
Nakamura F et al. Intern Med, February 2025 – open access publication
|
Circumventing imatinib resistance in chronic myeloid leukemia: Novel Telmirsatan-based cell death modulators with improved activity and stability
Gebhart M et al. Eur J Med Chem, February 2025
– open access publication |
Ophthalmic findings leading to diagnose chronic myeloid leukemia: A multimodal image case report
Hoyos A et al. Eur J Ophthalmol, February 2025 (epub ahead of print) |
Proliferation inhibited by Genipin in human leukemia K562 cells:
Involvement of uncoupling protein 2 in mitochondrial damage
Zhou Y et al. World J Oncol, February 2025
(epub ahead of print)
– open access publication
|
Asciminib in the treatment of chronic myeloid leukemia chronic phase – Review
Costa A et al. Future Oncol, February 2025
(epub ahead of print) |
CML with mutant ASXL1 showed decreased sensitivity to TKI treatment via upregulation of the ALOX5-BLTR Signaling Pathway
Miyashita N et al. Cancer Sci, February 2025
(epub ahead of print)
– open access publication |
A nomogram for predicting T315I-free survival in chronic-phase chronic myeloid leukemia patients: A multicentre retrospective study
Hu SW et al. Sci Rep, February 2025
– open access publication |
|
Introduction to a series of reflections on a quarter century of TKIs for CML
Druker BJ. Blood, February 2025
– open access publication |
|
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1 / 2 trial
Cortes JE et al. Lancet Haematol, February 2025 (epub ahead of print) |
|
Blast-phase chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia
Shuyu E et al. Am J Clin Pathol, February 2025 |
|
Inflammatory/immune adverse events in chronic myeloid leukemia patients during treatment with Bosutinib
Agostani E et al. Cancer Med, February 2025 – open access publication |
|
Total psoriasis regression in a patient with chronic myeloid leukemia treated using Nilotinib
Horňák T et al. Ann Hematol, February 2025
(epub ahead of print) – open access publication |
|
Fibrosis and treatment-free remission in chronic myeloid leukemia
Brailovski E et al. Br J Haematol, February 2025
(epub ahead of print) |
|
BCR::ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using a US Food and Drug Administration-approved droplet-based PCR assay
Kockerols C et al. J Mol Diagn, February 2025 – open access publication |
|
Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia
Abumiya M et al. Int J Hematol, February 2025
(epub ahead of print) – open access publication |
|
Treatment-free remission outcomes in BCR::ABL1 digital PCR selected clinical cohort of chronic myeloid leukemia patients
Kockerols C et al. Eur J Haematol, February 2025
(epub ahead of print)
– open access publication |
|
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukemia
Gong X et al. Leukemia, February 2025
(epub ahead of print)
– open access publication |
|
Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia
Chen EY et al. Eur J Haematol, February 2025
– open access publication |
|
| January 2025 |
Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: A phase 1b randomized clinical trial
Jabbour E et al. JAMA Oncol, January 2025
|
Design and fabrication of novel microfluidic-based droplets for drug screening on a chronic myeloid leukemia cell line
Jaafari N et al. PLoS, January 2025
– open access publication
|
Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life
Cho HJ et al. Acta Haematol, January 2025 (epub ahead of print)
|
Exploring the significance of MDM2 gene promotes variants in chronic myeloid leukemia
Fontecha MB et al. Leuk Res, January 2025 (epub ahead of print)
|
Bosutinib for the treatment of CML – using it safely: a Podcast
Lipton JH and Cortes JE. Target Oncol, January 2025 (epub ahead of print)
– open access publication |
N-Degron PROTACs as a potential therapeutic approach for chronic myeloid leukemia
Hohmann G & Eldeeb MA. Anticancer Agents Med Chem, January 2025
(epub ahead of print)
|
The evolution of treatment-free remission
Hughes TP et al. Blood, January 2025
(epub ahead of print) |
Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL positive leukemia
Luo Z et al. Cancer Res, January 2025
– open access publication
|
The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
Qian Z et al. Bioorg Chem, January 2025
(epub ahead of print) |
Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells
Sun X et al. Biochem Pharmacol, January 2025 (epub ahead of print)
|
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukemia: Are women and men different?
Maduado C et al. ESC Heart Fail, January 2025
(epub ahead of print)
– open access publication |
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia
Minhajuddin M et al. Haematologica, January 2025 – open access publication |
Efficacy and safety of the first-in-class STAMP inhibitor asciminib in patients with chronic myeloid leukemia – Review
Ureshino H and Kimura S. Clin Lymphoma Myeloma Leuk, January 2025 |
LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting
Quijada-Alamo M et al. Haematologica, January 2025 – open access publication |
Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia
Li Z et al. Cancer, January 2025
– open access publication |
Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
Komic H et al. Haematologica, January 2025 – open access publication |
Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib
Yu L et al. Cancer, January 2025
– open access publication |
High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell toxicity in chronic myeloid leukemia
Nygren PJ et al. Blood, January 2025 (epub ahead of print) |
Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid)
Sasaki K. Cancer, January 2025 |
Tyrosine kinase inhibitor therapy enhances stem cells profile and may contribute to survival of chronic myeloid leukemia stem cells
Rocco S et al. J Clin Med, January 2025
– open access publication |
Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
Kondo T et al. Cancer, January 2025
– open access publication |
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in chronic myeloid leukemia
Brunmeier R et al. Leukemia, January 2025
(epub ahead of print)
– open access publication |
Impact of first- and second-generation tyrosine kinase inhibitors on the development of graft-versus host disease in individuals with CML: A retrospective analysis on behalf of the Polish Adult Leukemia Group
Giordano U et al. Biomedicines, January 2025
- open access publication |
|
Clinical and prognostic significance of additional chromosomal abnormalities at diagnosis of chronic myeloid leukemia
Mayer J et al. Am J Hematol, January 2025
(epub ahead of print)
– open access publication |
|
Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases
Yousefi A et al. Ann Hematol, January 2025
(epub ahead of print)
– open access publication |
|
Asciminib versus bosutinib following two or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study
Szuber N et al. Future Oncol, January 2025
(epub ahead of print)
– open access publication |
|
Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice
Aleem A et al. Clin Lymphoma Myeloma Leuk,
January 2025 |
|
Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on TKI therapy
Shen Q et al. Leuk Lymphoma, January 2025
(epub ahead of print) |
|
English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
